Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted

Last week, the FDA issued a total of 4 orphan drug qualifications, including 3 small molecule targeted drugs and 1 fusion protein, including the IL-2 selective agonist nemvaleukin alfa (ALKS 4230) developed by Alkermes to treat mucosal melanoma.

Drug: Nemvaleukin alfa

R&D company: Alkermes

Treatment of disease: mucosal melanoma (mucosal melanoma)

Introduction: Nemvaleukin alfa is an innovative engineering fusion protein under research, which is composed of modified interleukin-2 (IL-2) and a high-affinity IL-2α receptor chain, designed to selectively amplify tumor-killing effects Immune cells, while avoiding activating immunosuppressive cells.

Drug: Ubenimex (ubenimex)

Research and development company: RNR BioMedical

Treatment of diseases: chronic myeloid leukemia (CML)

Introduction: Chronic myelogenous leukemia (CML) is a malignant myeloproliferative tumor that occurs on pluripotent hematopoietic stem cells.

Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.

[1] Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma.

▽ attention [drug Mingkang Germany ] micro-channel public number